Plain-English translation of NCT06958328 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether higher doses of radiation therapy can improve survival for people with locally advanced pancreatic cancer that cannot be surgically removed. After you receive several months of chemotherapy, you will be randomly assigned to either continue with standard treatment or receive a newer, higher-dose radiation approach. The goal is to see if the intensified radiation helps you live longer and controls the cancer better.
Pancreatic cancer is very aggressive, and patients with locally advanced disease have limited treatment options. This trial exists because doctors believe that delivering higher doses of radiation therapy might be more effective at destroying cancer cells while keeping side effects manageable, potentially improving survival compared to what we can achieve today.
You likely qualify if…
You likely don't qualify if…
After completing your initial chemotherapy, you will be randomly assigned to one of two groups. The standard care group will continue with chemotherapy alone or receive standard-dose radiation with chemotherapy, based on your doctor's recommendation. The higher-dose radiation group will receive intensified radiation therapy over either 5 sessions or 25 daily sessions, with or without concurrent chemotherapy. Throughout the study, you will have regular blood tests, imaging scans (CT, MRI, and possibly PET/CT), and possibly a tumor biopsy to monitor your progress and quality of life.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States